Your browser doesn't support javascript.
loading
Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion (Zalophus californianus) and Pacific harbor seal (Phoca vitulina richardii).
Trumbull, Emily J; Papich, Mark G; Peters, Mattison; Whitmer, Emily R; Rivard, Michelle; Field, Cara L.
Afiliação
  • Trumbull EJ; County of San Diego, San Diego, California, USA.
  • Papich MG; SeaWorld, San Diego, California, USA.
  • Peters M; College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
  • Whitmer ER; The Marine Mammal Center, Sausalito, California, USA.
  • Rivard M; The Marine Mammal Center, Sausalito, California, USA.
  • Field CL; SR3 (SeaLife Response, Rehab, Research), Des Moines, Washington, USA.
J Vet Pharmacol Ther ; 2024 Jul 14.
Article em En | MEDLINE | ID: mdl-39003597
ABSTRACT
Pharmacokinetics studies have investigated meloxicam, a non-steroidal anti-inflammatory drug, dosing strategies in a wide variety of non-domestic animals; however, there is no prior study examining well-founded dosing for pinnipeds. To develop dosing protocols, pharmacokinetic information is needed, with an examination of differences between pinniped species. Apparently, healthy California sea lions (Zalophus californianus CSL; n = 13) and Pacific harbor seals (Phoca vitulina richardii PHS; n = 17) that had completed rehabilitation were enrolled into a population-based pharmacokinetic study. Each animal was administered a single oral dose of meloxicam at 0.1 mg/kg, and two blood samples were collected from each animal at varying intervals during a 96-h study period. Plasma concentrations of meloxicam were determined by high-pressure liquid chromatography. Data were analyzed with nonlinear mixed effects modeling (Phoenix® NLME™, Certara, St. Louis, MO 63105, USA). The results indicated that in PHS, peak plasma concentration (Cmax) was 0.33 µg/mL with an elimination half-life (Ke t½) of 31.53 h. In CSL, Cmax was 0.17 µg/mL with Ke t½ of 32.71 h. All animals enrolled completed the study without outward adverse clinical signs. The elimination half-life was longer than previously recommended dosing intervals for pinnipeds; however, we cannot speculate in the optimum clinical dose from these results.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article